1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1159/000075627" target="_blank" rel="noreferrer noopener">http://doi.org/10.1159/000075627</a> Rights Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). Pages 32-40 Issue 1 Volume 24 Search for Full-text Locate full-text within NEOMED Library's e-journal collections <p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy Publisher An entity responsible for making the resource available American Journal of Nephrology Date A point or period of time associated with an event in the lifecycle of the resource 2004 2004 Subject The topic of the resource kidney; disease; Urology & Nephrology; mellitus; rats; progression; nephropathy; advanced glycation end product inhibition diabetic; albuminuria; aminoguanidine; diabetic retinopathy; hydralazine; pimagedine; protein glycation Creator An entity primarily responsible for making the resource Bolton W K; Cattran D C; Williams M E; Adler S G; Appel G B; Cartwright K; Foiles P G; Freedman B I; Raskin P; Ratner R E; Spinowitz B S; Whittier F C; Wuerth J P; Grp Action I Investigator Description An account of the resource Background/Aims: Pimagedine inhibits the formation of advanced glycation end products and slows the progression of diabetic complications in experimental models. This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 ( insulin-dependent) diabetes mellitus. Methods: This was a randomized, double-masked, placebo-controlled study performed in 690 patients with type 1 diabetes mellitus, nephropathy, and retinopathy. The patients received twice daily dosing with placebo, pimagedine 150 mg, or pimagedine 300 mg for 2 - 4 years. The primary end point was the time to doubling of serum creatinine; the secondary end points included evaluations of proteinuria, kidney function, and retinopathy. Results: Serum creatinine doubled in 26% (61/236) of the placebo-treated patients and in 20% (91/454) of those who received pimagedine ( p = 0.099). The estimated glomerular filtration rate decreased more slowly in the pimagedine-treated patients with a 36-month decrease from baseline of 6.26 ml/min/ 1.73 m(2) as compared with 9.80 ml/ min/1.73 m(2) in the placebo-treated patients ( p = 0.05), and pimagedine reduced the 24-hour total urinary proteinuria. ( The mean reduction from baseline at month 36 was 732 mg/24 h at the low dose and 329 mg/24 h at the high dose as compared with 35 mg/24 h in the placebo group; p less than or equal to 0.001.) Fewer pimagedine-treated patients with baseline and end point evaluations (31/324; 10%) as compared with those receiving placebo (16%; 28/179) experienced a three-step or greater progression of the retinopathy ( Early Treatment of Diabetic Retinopathy Study) score ( p = 0.030). Three patients receiving high-dose pimagedine but none receiving low-dose treatment developed glomerulonephritis. Conclusions: While this study did not demonstrate a statistically significant beneficial effect of pimagedine on the progression of overt nephropathy resulting from type 1 diabetes, it is noteworthy in providing the first clinical proof of the concept that inhibiting advanced glycation end product formation can result in a clinically important attenuation of the serious complications of type 1 diabetes mellitus. Copyright (C) 2004 S. Karger AG, Basel. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1159/000075627" target="_blank" rel="noreferrer noopener">10.1159/000075627</a> Format The file format, physical medium, or dimensions of the resource Journal Article or Conference Abstract Publication 2004 Adler S G advanced glycation end product inhibition diabetic albuminuria American journal of nephrology aminoguanidine Appel G B Bolton W K Cartwright K Cattran D C Department of Internal Medicine diabetic retinopathy Disease Foiles P G Freedman B I Grp Action I Investigator hydralazine Journal Article or Conference Abstract Publication Kidney mellitus NEOMED College of Medicine nephropathy pimagedine progression protein glycation Raskin P Ratner R E Rats Spinowitz B S Urology & Nephrology Whittier F C Williams M E Wuerth J P